Literature DB >> 1252270

Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus.

R B Zurier.   

Abstract

Serums from 22 of 30 (73.3%) patients with systemic lupus erythematosus (SLE) interfered significantly with particle (zymosan) uptake and subsequent release from normal human neutrophils of lysosomal enzymes. SLE serums with low as well as those with normal functional hemolytic complement activity (CH50) suppressed phagocytosis and enzyme release despite the presence of normal serum in cell suspensions. The defect did not appear to be caused by anticomplementary activity of serum. Serums from patients whose clinical activity of disease varied from none to severe and whose treatment varied from none to high doses of prednisone were capable of suppressing phagocytosis and enzyme release. The severity of clinical SLE activity did not affect the degree of suppression. Serums from patients treated with corticosteroids were more inhibitory than serums from patients not so treated. The nature of the inhibitor is unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1252270     DOI: 10.1002/art.1780190112

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Circulating immune complexes and monocyte Fc function in autoimmune diseases.

Authors:  M Kávai; K Lukács; I Sonkoly; K Páloczi; G Szegedi
Journal:  Ann Rheum Dis       Date:  1979-02       Impact factor: 19.103

2.  Autoreactive MZ and B-1 B-cell activation by Faslpr is coincident with an increased frequency of apoptotic lymphocytes and a defect in macrophage clearance.

Authors:  Ye Qian; Kara L Conway; Xiangdong Lu; Heather M Seitz; Glenn K Matsushima; Stephen H Clarke
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  Anti-SSB/La is one of the antineutrophil autoantibodies responsible for neutropenia and functional impairment of polymorphonuclear neutrophils in patients with systemic lupus erythematosus.

Authors:  S-C Hsieh; H-S Yu; W-W Lin; K-H Sun; C-Y Tsai; D-F Huang; Y-Y Tsai; C-L Yu
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

4.  Presence of antibodies to SSB/La is associated with decreased phagocytic efficiency of neutrophils in patients with systemic lupus erythematosus.

Authors:  Debasis Biswas; Amrita Mathias; Rajeshwar Dayal; Amita Aggarwal; Ramnath Misra; Sita Naik
Journal:  Clin Rheumatol       Date:  2007-11-06       Impact factor: 2.980

Review 5.  Phagocytosis. Clinical disorders of recognition and ingestion.

Authors:  T P Stossel
Journal:  Am J Pathol       Date:  1977-09       Impact factor: 4.307

6.  A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.

Authors:  H D Perez; M Lipton; I M Goldstein
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

7.  Neutrophil function in systemic lupus erythematosus and other collagen diseases.

Authors:  H Al-Hadithy; D A Isenberg; I E Addison; A H Goldstone; M L Snaith
Journal:  Ann Rheum Dis       Date:  1982-02       Impact factor: 19.103

8.  Abnormal monocyte cytotoxicity and cyclic-AMP levels in systemic sclerosis.

Authors:  T Herlin; J Eggert; K Kragballe; H Zachariae
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.